Breast Cancer News

Sara M. Tolaney, MD, MPH, breast medical oncologist from Dana-Farber Cancer Institute, discussed the long-term follow-up data of 4-year outcomes from the NATALEE trial.

Trastuzumab deruxtecan, or T-DXd, showed clinical activity in a large population of metastatic HER2-positive breast cancer patients with brain metastases, according to “really impressive” data from DESTINYBreast-12 presented at ESMO Congress.

Sara M. Tolaney, MD, MPH, breast medical oncologist from Dana-Farber Cancer Institute, talked about survival data from KEYNOTE-522 that have been awaited with “a lot of anticipation.”

For many oncologists, the use of mastectomy to treat breast cancer cases can be a difficult subject to approach with patients.

ORLANDO — Mass General Cancer Center has found success in an oncology-focused lifestyle medicine clinic, proving that the model can be sustainable and beneficial, according to a poster presented at the Lifestyle Medicine Conference.

Women who breastfeed after undergoing treatment for breast cancer are not at elevated risk for recurrence or new breast cancers, two studies presented at ESMO Congress showed.

Individuals with cancer expressed a preference for early and frequent provider-initiated discussions about financial toxicity, according to study findings.

Laura J. van ’t Veer, PhD, will receive the William L. McGuire Memorial Lecture Award at this year’s San Antonio Breast Cancer Symposium, scheduled for Dec. 10-13.

A voice-activated, in-home cognitive behavioral therapy program alleviated symptoms of insomnia among breast cancer survivors, according to results of a randomized clinical trial.

Hypofractionated radiation therapy after breast cancer surgery significantly reduced risk for adverse events and improved quality of life compared with a conventional radiation therapy schedule, according to study results.